Opposing oncogenic activities of small DNA tumor virus transforming proteins

Trends in Microbiology

Volumn 19, Issue 4, 2011, Pages 174-183

  Chinnadurai, G ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; RETINOBLASTOMA PROTEIN;

CANCER INHIBITION; CARCINOGENESIS; CELL IMMORTALIZATION; CELL ONCOGENE; CELL PROLIFERATION; CELL TRANSFORMATION; EPITHELIUM CELL; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VIRUS ONCOGENE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; HUMANS; ONCOGENE PROTEINS, VIRAL; TUMOR SUPPRESSOR PROTEINS; VIRULENCE FACTORS;

HUMAN ADENOVIRUS; PAPILLOMAVIRIDAE;

EID: 79953289599     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2011.01.003     Document Type: Review

References (88)

1. Javier R.T., Butel J.S. The history of tumor virology. Cancer Res. 2008, 68:7693-7706.
2. DeCaprio J.A. How the Rb tumor suppressor structure and function was revealed by the study of adenovirus and SV40. Virology 2009, 384:274-284.
3. Graham F.L., et al. Size and location of the transforming region in human adenovirus type 5 DNA. Nature 1974, 251:687-691.
4. Ruley H.E. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983, 304:602-606.
5. Pelka P., et al. Intrinsic structural disorder in adenovirus E1A: a viral molecular hub linking multiple diverse processes. J. Virol. 2008, 82:7252-7263.
6. Gallimore P.H., Turnell A.S. Adenovirus E1A: remodelling the host cell, a life or death experience. Oncogene 2001, 20:7824-7835.
7. Wang H.G., et al. Identification of specific adenovirus E1A N-terminal residues critical to the binding of cellular proteins and to the control of cell growth. J. Virol. 1993, 67:476-488.
8. Eckner R., et al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 1994, 8:869-884.
9. Arany Z., et al. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995, 374:81-84.
10. Fuchs M., et al. The p400 complex is an essential E1A transformation target. Cell 2001, 106:297-307.
11. Deleu L., et al. Recruitment of TRRAP required for oncogenic transformation by E1A. Oncogene 2001, 20:8270-8275.
12. Lang S.E., Hearing P. The adenovirus E1A oncoprotein recruits the cellular TRRAP/GCN5 histone acetyltransferase complex. Oncogene 2003, 22:2836-2841.
13. Kulesza C.A., et al. Adenovirus E1A requires the yeast SAGA histone acetyltransferase complex and associates with SAGA components Gcn5 and Tra1. Oncogene 2002, 21:1411-1422.
14. Ferguson E.L., Horvitz H.R. The multivulva phenotype of certain Caenorhabditis elegans mutants results from defects in two functionally redundant pathways. Genetics 1989, 123:109-121.
15. Ceol C.J., Horvitz H.R. dpl-1 DP and efl-1 E2F act with lin-35 Rb to antagonize Ras signaling in C. elegans vulval development. Mol. Cell 2001, 7:461-473.
16. Ceol C.J., Horvitz H.R. A new class of C. elegans synMuv genes implicates a Tip60/NuA4-like HAT complex as a negative regulator of Ras signaling. Dev. Cell 2004, 6:563-576.
17. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14:1553-1577.
18. Horwitz G.A., et al. Adenovirus small e1a alters global patterns of histone modification. Science 2008, 321:1084-1085.
19. Ferrari R., et al. Epigenetic reprogramming by adenovirus e1a. Science 2008, 321:1086-1088.
20. Sankar N., et al. p300 provides a corepressor function by cooperating with YY1 and HDAC3 to repress c-Myc. Oncogene 2008, 27:5717-5728.
21. Kadeppagari R.K., et al. Adenovirus transforming protein E1A induces c-Myc in quiescent cells by a novel mechanism. J. Virol. 2009, 83:4810-4822.
22. Singhal G., et al. Simian virus 40 large T overcomes p300 repression of c-Myc. Virology 2008, 377:227-232.
23. Turnell A.S., et al. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 2005, 438:690-695.
24. Nikiforov M.A., et al. TRRAP-dependent and TRRAP-independent transcriptional activation by Myc family oncoproteins. Mol. Cell. Biol. 2002, 22:5054-5063.
25. Ikura T., et al. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 2000, 102:463-473.
26. Sterner D.E., Berger S.L. Acetylation of histones and transcription-related factors. Microbiol. Mol. Biol. Rev. 2000, 64:435-459.
27. McMahon S.B., et al. The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 1998, 94:363-374.
28. McMahon S.B., et al. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. Mol. Cell. Biol. 2000, 20:556-562.
29. Frank S.R., et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 2001, 15:2069-2082.
30. Frank S.R., et al. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 2003, 4:575-580.
31. Patel J.H., et al. The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol. Cell. Biol. 2004, 24:10826-10834.
32. Lohr K., et al. Mutual interference of adenovirus infection and myc expression. J. Virol. 2003, 77:7936-7944.
33. Tworkowski K.A., et al. Adenovirus E1A targets p400 to induce the cellular oncoprotein Myc. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6103-6108.
34. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
35. Whyte P., et al. Cellular targets for transformation by the adenovirus E1A proteins. Cell 1989, 56:67-75.
36. Liu X., Marmorstein R. Structure of the retinoblastoma protein bound to adenovirus E1A reveals the molecular basis for viral oncoprotein inactivation of a tumor suppressor. Genes Dev. 2007, 21:2711-2716.
37. Nevins J.R. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992, 258:424-429.
38. Seifried L.A., et al. pRB-E2F1 complexes are resistant to adenovirus E1A-mediated disruption. J. Virol. 2008, 82:4511-4520.
39. Nemajerova A., et al. Rb function is required for E1A-induced S-phase checkpoint activation. Cell Death Differ. 2008, 15:1440-1449.
40. Webster K.A., et al. Adenovirus E1A products suppress myogenic differentiation and inhibit transcription from muscle-specific promoters. Nature 1988, 332:553-557.
41. Mymryk J.S., et al. Ability of adenovirus 5 E1A proteins to suppress differentiation of BC3H1 myoblasts correlates with their binding to a 300 kDa cellular protein. Mol. Biol. Cell 1992, 3:1107-1115.
42. Subramanian T., et al. Enhanced ras oncogene mediated cell transformation and tumorigenesis by adenovirus 2 mutants lacking the C-terminal region of E1a protein. Oncogene 1989, 4:415-420.
43. Chinnadurai G. Adenovirus E1a as a tumor-suppressor gene. Oncogene 1992, 7:1255-1258.
44. Douglas J.L., et al. Modulation of transformation of primary epithelial cells by the second exon of the Ad5 E1A12S gene. Oncogene 1991, 6:2093-2103.
45. Quinlan M.P., Douglas J.L. Immortalization of primary epithelial cells requires first- and second-exon functions of adenovirus type 5 12S. J. Virol. 1992, 66:2020-2030.
46. Frisch S.M. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:9077-9081.
47. Frisch S.M. E1a induces the expression of epithelial characteristics. J. Cell Biol. 1994, 127:1085-1096.
48. Fischer R.S., Quinlan M.P. The C terminus of E1A regulates tumor progression and epithelial cell differentiation. Virology 1998, 249:427-439.
49. Boyd J.M., et al. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phosphoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 1993, 12:469-478.
50. Schaeper U., et al. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:10467-10471.
51. Komorek J., et al. Adenovirus type 5 E1A and E6 proteins of low-risk cutaneous beta-human papillomaviruses suppress cell transformation through interaction with FOXK1/K2 transcription factors. J. Virol. 2010, 84:2719-2731.
52. Zhang Z., et al. Interaction of the E1A oncoprotein with Yak1p, a novel regulator of yeast pseudohyphal differentiation, and related mammalian kinases. Mol. Biol. Cell 2001, 12:699-710.
53. Chinnadurai G. CtBP, an unconventional transcriptional corepressor in development and oncogenesis. Mol. Cell 2002, 9:213-224.
54. Chinnadurai G. Transcriptional regulation by C-terminal binding proteins. Int. J. Biochem. Cell Biol. 2007, 39:1593-1607.
55. Grooteclaes M.L., Frisch S.M. Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 2000, 19:3823-3828.
56. Phelps R.A., et al. A two-step model for colon adenoma initiation and progression caused by APC loss. Cell 2009, 137:623-634.
57. Grooteclaes M., et al. C-terminal-binding protein corepresses epithelial and proapoptotic gene expression programs. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4568-4573.
58. Kovi R.C., et al. An ARF/CtBP2 complex regulates BH3-only gene expression and p53-independent apoptosis. Cell Death Differ. 2010, 17:513-521.
59. Paez J., Sellers W.R. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat. Res. 2003, 115:145-167.
60. Durocher D., Jackson S.P. The FHA domain. FEBS Lett. 2002, 513:58-66.
61. Mahajan A., et al. Structure and function of the phosphothreonine-specific FHA domain. Sci. Signal. 2008, 1:re12.
62. Martin C.M., et al. Molecular signatures define myogenic stem cell populations. Stem Cell Rev. 2006, 2:37-42.
63. Hawke T.J., et al. Absence of p21CIP rescues myogenic progenitor cell proliferative and regenerative capacity in Foxk1 null mice. J. Biol. Chem. 2003, 278:4015-4020.
64. Meeson A.P., et al. Cellular and molecular regulation of skeletal muscle side population cells. Stem Cells 2004, 22:1305-1320.
65. Marais A., et al. Cell cycle-dependent regulation of the forkhead transcription factor FOXK2 by CDK.cyclin complexes. J. Biol. Chem. 2010, 285:35728-35739.
66. Zhu G., et al. Two yeast forkhead genes regulate the cell cycle and pseudohyphal growth. Nature 2000, 406:90-94.
67. Yang Q., et al. The winged-helix/forkhead protein myocyte nuclear factor beta (MNF-beta) forms a co-repressor complex with mammalian sin3B. Biochem. J. 2000, 345(Pt 2):335-343.
68. Freddie C.T., et al. Functional interactions between the Forkhead transcription factor FOXK1 and the MADS-box protein SRF. Nucleic Acids Res. 2007, 35:5203-5212.
69. Fernandez-Martinez J., et al. Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A. J. Cell Sci. 2009, 122:1574-1583.
70. Arron J.R., et al. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature 2006, 441:595-600.
71. Gwack Y., et al. A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature 2006, 441:646-650.
72. Mao J., et al. Regulation of Gli1 transcriptional activity in the nucleus by Dyrk1. J. Biol. Chem. 2002, 277:35156-35161.
73. Friedman E. Mirk/Dyrk1B in cancer. J. Cell. Biochem. 2007, 102:274-279.
74. Nissen R.M., et al. A zebrafish screen for craniofacial mutants identifies wdr68 as a highly conserved gene required for endothelin-1 expression. BMC Dev. Biol. 2006, 6:28.
75. Jaspersen S.L., et al. A late mitotic regulatory network controlling cyclin destruction in Saccharomyces cerevisiae. Mol. Biol. Cell 1998, 9:2803-2817.
76. Feng H., et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319:1096-1100.
77. Le B.M., et al. Clinical and epidemiologic characterization of WU polyomavirus infection, St. Louis, Missouri. Emerg. Infect. Dis. 2007, 13:1936-1938.
78. Allander T., et al. Identification of a third human polyomavirus. J. Virol. 2007, 81:4130-4136.
79. Schowalter R.M., et al. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe 2010, 7:509-515.
80. Shuda M., et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16272-16277.
81. Straza M.W., et al. Therapeutic targeting of C-terminal binding protein in human cancer. Cell Cycle 2010, 9:3740-3750.
82. Chow L.T., et al. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 2010, 118:422-449.
83. Orth G., et al. Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res. 1979, 39:1074-1082.
84. Howie H.L., et al. Papillomavirus E6 proteins. Virology 2009, 384:324-334.
85. Hellner K., et al. HPV16 E7 oncogene expression in normal human epithelial cells causes molecular changes indicative of an epithelial to mesenchymal transition. Virology 2009, 391:57-63.
86. Kiyono T., et al. Differences in transforming activity and coded amino acid sequence among E6 genes of several papillomaviruses associated with epidermodysplasia verruciformis. Virology 1992, 186:628-639.
87. Marcuzzi G.P., et al. Spontaneous tumour development in human papillomavirus type 8 E6 transgenic mice and rapid induction by UV-light exposure and wounding. J. Gen. Virol. 2009, 90:2855-2864.
88. Jackson S., et al. Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000, 14:3065-3073.